Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23584920 | 0.92 | BACE1 (0.39) | BACE1GLANPSR1TDP1POLB | |
| SCHEMBL21176880 | 0.86 | HPGD (0.46) | BACE1GLANPSR1TDP1GAA | |
| SCHEMBL5642127 | 0.85 | BACE1 (0.42) | BACE1GLANPSR1POLBALDH1A1 | |
| SCHEMBL25353819 | 0.85 | L3MBTL1 (0.40) | BACE1GLANPSR1POLBCTBP2 | |
| SCHEMBL31048329 | 0.85 | BACE1 (0.40) | BACE1GLANPSR1TDP1SMN1; SMN2 | |
| SCHEMBL30706753 | 0.85 | BACE1 (0.40) | BACE1GLANPSR1SMN1; SMN2LMNA | |
| SCHEMBL8320979 | 0.84 | BACE1 (0.42) | BACE1GLANPSR1SMN1; SMN2LMNA | |
| SCHEMBL31551850 | 0.84 | BACE1 (0.41) | BACE1GLANPSR1HTTKDM4E | |
| SCHEMBL8240783 | 0.81 | CYP1A2 (0.43) | GAASMN1; SMN2LMNAKMT2AHTT | |
| SCHEMBL24535005 | 0.81 | PIK3CA (0.43) | BACE1GLANPSR1HTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4655073-A2 | CEREBLON-BASED KRAS DEGRADING PROTACS ANS USES RELATED THERETO | Arvinas Operations, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | ARVINAS OPERATIONS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119677749-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-8558000-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-15 | — | — | US | disclosed |
| EP-2235002-B1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL MYERS SQUIBB CO (US) | 2012-11-21 | — | — | EP | disclosed |
| US-8258118-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-04 | — | — | US | disclosed |
| US-20120114643-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-10 | — | — | US | disclosed |
| US-8124768-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY | 2011-02-10 | — | — | US | disclosed |
| EP-2235002-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | Bristol-Myers Squibb Company (US) | 2010-10-06 | — | — | EP | disclosed |
| EP-2235001-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | Bristol-Myers Squibb Company (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009094427-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094417-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034416-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | DPYD, CDK4, G6PD | BACE1 4499/4885GLA 1877/4885NPSR1 3812/4885 |
| US-12448399-B2 | Cereblon-based KRAS degrading PROTACs and uses related thereto | CRBN, KRAS, WEE1 | BACE1 472/4885GLA 2358/4885NPSR1 4818/4885 |
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | BACE1 2184/4885GLA 2200/4885NPSR1 4736/4885 |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | BACE1 2598/4885GLA 3089/4885NPSR1 4609/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | BACE1 3592/4885GLA 3535/4885NPSR1 4157/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | BACE1 2558/4885GLA 2688/4885NPSR1 4225/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | BACE1 1135/4885GLA 2835/4885NPSR1 4476/4885 |
| US-20120114643-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | DPYD, CDK4, G6PD | BACE1 4499/4885GLA 1877/4885NPSR1 3812/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | BACE1 3729/4885GLA 3033/4885NPSR1 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.